Trial Profile
A Phase 1/2 study of ONO-7057 in patients with relapsed and/or refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 01 Sep 2019 Final results published in the Cancer Science
- 01 Mar 2016 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Haematology.
- 30 Nov 2011 New trial record